PMID- 22658515
OWN - NLM
STAT- MEDLINE
DCOM- 20130317
LR  - 20130114
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Linking)
VI  - 85
IP  - 2
DP  - 2013 Feb 1
TI  - Outcomes of patients with revised stage I clear cell sarcoma of kidney treated in 
      National Wilms Tumor Studies 1-5.
PG  - 428-31
LID - S0360-3016(12)00570-6 [pii]
LID - 10.1016/j.ijrobp.2012.04.023 [doi]
AB  - PURPOSE: To report the clinical outcomes of children with revised stage I clear 
      cell sarcoma of the kidney (CCSK) using the National Wilms Tumor Study Group 
      (NWTS)-5 staging criteria after multimodality treatment on NWTS 1-5 protocols. 
      METHODS AND MATERIALS: All CCSK patients enrolled in the National Wilms Tumor 
      Study Group protocols had their pathology slides reviewed, and only those 
      determined to have revised stage I tumors according to the NWTS-5 staging 
      criteria were included in the present analysis. All patients were treated with 
      multimodality therapy according to the NWTS 1-5 protocols. RESULTS: A total of 53 
      children were identified as having stage I CCSK. All patients underwent primary 
      surgery with radical nephrectomy. The chemotherapy regimens used were as follows: 
      regimen A, C, F, or EE in 4 children (8%); regimen DD or DD4A in 33 children 
      (62%); regimen J in 4 children (8%); and regimen I in 12 children (22%). 
      Forty-six patients (87%) received flank radiation therapy (RT). Seven children 
      (13%) did not receive flank RT. The median delay between surgery and the 
      initiation of RT was 9 days (range, 3-61). The median RT dose was 10.8 Gy (range, 
      10-36). The flank RT doses were as follows: 10.5 or 10.8 Gy in 25 patients (47%), 
      11-19.9 Gy in 2 patients (4%), 20-29.9 Gy in 9 patients (17%), and 30-40 Gy in 10 
      patients (19%). The median follow-up for the entire group was 17 years (range, 
      2-36). The relapse-free and cancer-specific survival rate was 100% at the last 
      follow-up examination. CONCLUSIONS: The present results have demonstrated that 
      children with revised stage I CCSK using the NWTS-5 staging criteria have 
      excellent survival rates despite the use of varying RT doses and chemotherapy 
      regimens in the NWTS 1-5 protocols.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Kalapurakal, John A
AU  - Kalapurakal JA
AD  - Northwestern University, Chicago, Illinois, USA. j-kalapurakal@northwestern.edu
FAU - Perlman, Elizabeth J
AU  - Perlman EJ
FAU - Seibel, Nita L
AU  - Seibel NL
FAU - Ritchey, Michael
AU  - Ritchey M
FAU - Dome, Jeffrey S
AU  - Dome JS
FAU - Grundy, Paul E
AU  - Grundy PE
LA  - eng
GR  - CA-42326/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120601
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy/adverse effects/methods
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Kidney Neoplasms/mortality/pathology/*therapy
MH  - Male
MH  - Neoplasm Staging/methods
MH  - Neoplasms, Second Primary/etiology
MH  - Nephrectomy/methods
MH  - Radiotherapy/methods
MH  - Radiotherapy Dosage
MH  - Sarcoma, Clear Cell/mortality/pathology/*therapy
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/06/05 06:00
MHDA- 2013/03/19 06:00
CRDT- 2012/06/05 06:00
PHST- 2012/03/19 00:00 [received]
PHST- 2012/04/11 00:00 [revised]
PHST- 2012/04/12 00:00 [accepted]
PHST- 2012/06/05 06:00 [entrez]
PHST- 2012/06/05 06:00 [pubmed]
PHST- 2013/03/19 06:00 [medline]
AID - S0360-3016(12)00570-6 [pii]
AID - 10.1016/j.ijrobp.2012.04.023 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):428-31. doi: 
      10.1016/j.ijrobp.2012.04.023. Epub 2012 Jun 1.